Evidence map›Paper›PMID 41979160›Full record

ArticleClinical and translational science2026

Positioning Community Pharmacies in Nigeria as a Clinical Trial Partner: A Forward Perspective.

Adeboye O Bamgboye, Ibrahim A Hassan, Babatunde M Jinadu, Luke A Alade, Tobechi B Nnanna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adeboye O BamgboyeDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0003-2681-0899
Ibrahim A HassanFaculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0000-0002-5995-6272
Babatunde M JinaduFaculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0009-0008-2215-6483
Luke A AladeClinton Health Access International, Abuja, Nigeria.ORCID 0009-0001-3081-5839
Tobechi B NnannaAston Pharmacy School, College of Life and Health Sciences, Aston University, Birmingham, UK.ORCID 0000-0001-9702-6124

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Decentralized clinical trials (DCTs) employ innovative approaches to conduct research outside traditional clinical sites. Low- and middle-income countries like Nigeria, with limited infrastructure, insufficient manpower, and inadequate financial support for trials, can benefit from DCTs. By leveraging non-traditional infrastructure, such as community pharmacies, DCT approaches could overcome some infrastructural and recruitment challenges common in clinical trials in African countries. The extensive community pharmacy network in Nigeria could be strategically positioned as partners in DCT efforts.

Indexed as

Clinical Trials as TopicCommunity Pharmacy ServicesPharmaciesHumansNigeriaclinical trialscommunity pharmacydecentralized trialsNigeriaresearch infrastructure

Identifiers

PMID41979160
PMCPMC13077663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.